Insufficient Evidence for Rare Activation of Latent HIV in the Absence of Reservoir-Reducing Interventions

PLoS Pathogens

Volumn 12, Issue 8, 2016, Pages

  Hill, Alison L ^a   Rosenbloom, Daniel I S ^b   Siliciano, Janet D ^c   Siliciano, Robert F ^c,d  

^a HARVARD UNIVERSITY   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BAYES THEOREM; CLONE; COHORT ANALYSIS; GROWTH RATE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; MODEL; NONHUMAN; NORMAL HUMAN; REBOUND; SAMPLING; VIROGENESIS; VIRUS ACTIVATION; VIRUS CARRIER; VIRUS LOAD; VIRUS STRAIN; DRUG RESISTANCE; GENETIC VARIATION; HUMAN IMMUNODEFICIENCY VIRUS 1; VIRUS LATENCY;

DRUG RESISTANCE; GENETIC VARIATION; HIV-1; VIRUS LATENCY;

EID: 84984843571     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005679     Document Type: Article

References (21)

1. Hill AL, Rosenbloom DIS, Fu F, Nowak MA, Siliciano RF, Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. Proc Natl Acad Sci. 2014;111: 13475–13480. doi: 10.1073/pnas.140666311125097264
2. Pinkevych M, Cromer D, Tolstrup M, Grimm AJ, Cooper DA, Lewin SR, et al. HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5–8 Days—Implications for HIV Remission. PLoS Pathog. 2015;11: e1005000. doi: 10.1371/journal.ppat.100500026133551
3. Pennings PS, Standing Genetic Variation and the Evolution of Drug Resistance in HIV. PLoS Comput Biol. 2012;8: e1002527. doi: 10.1371/journal.pcbi.100252722685388
4. Rosenbloom DIS, Hill AL, Rabi SA, Siliciano RF, Nowak MA, Antiretroviral dynamics determines HIV evolution and predicts therapy outcome. Nat Med. 2012;18: 1378–1385. doi: 10.1038/nm.289222941277
5. Ribeiro RM, In vivo dynamics of T cell activation, proliferation, and death in HIV-1 infection: Why are CD4+ but not CD8+ T cells depleted?Proc Natl Acad Sci. 2002;99: 15572–15577. doi: 10.1073/pnas.24235809912434018
6. Rasmussen TA, Tolstrup M, Brinkmann CR, Olesen R, Erikstrup C, Solomon A, et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV. 2014;1: e13–e21. doi: 10.1016/S2352-3018(14)70014-126423811
7. Bloch MT, Smith DE, Quan D, Kaldor JM, Zaunders JJ, Petoumenos K, et al. The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: final results from a randomized clinical trial (Pulse). J Acquir Immune Defic Syndr. 2006;42: 192–202. doi: 10.1097/01.qai.0000219779.50668.e616688094
8. Davey RT, Jr.Bhat N, Yoder C, Chun T-W, Metcalf JA, Dewar R, et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA. 1999;96: 15109–15114. 10611346
9. Fischer M, Hafner R, Schneider C, Trkola A, Joos B, Joller H, et al. HIV RNA in plasma rebounds within days during structured treatment interruptions. AIDS Lond Engl. 2003;17: 195–199. doi: 10.1097/01.aids.0000042945.95433.4b
10. Ruiz L, Martinez-Picado J, Romeu J, Paredes R, Zayat MK, Marfil S, et al. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS. 2000;14: 397. 10770542
11. Ruiz L, Carcelain G, Martínez-Picado J, Frost S, Marfil S, Paredes R, et al. HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection. Aids. 2001;15: F19–F27. 11416734
12. Luo R, Piovoso MJ, Martinez-Picado J, Zurakowski R, HIV Model Parameter Estimates from Interruption Trial Data including Drug Efficacy and Reservoir Dynamics. PLoS ONE. 2012;7: e40198. doi: 10.1371/journal.pone.004019822815727
13. Eriksson S, Graf EH, Dahl V, Strain MC, Yukl SA, Lysenko ES, et al. Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies. PLoS Pathog. 2013;9: e1003174. doi: 10.1371/journal.ppat.100317423459007
14. Joos B, Fischer M, Kuster H, Pillai SK, Wong JK, Böni J, et al. HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A. 2008;105: 16725–16730. doi: 10.1073/pnas.080419210518936487
15. Fernàndez G, Clotet B, Martínez MA, Fitness Landscape of Human Immunodeficiency Virus Type 1 Protease Quasispecies. J Virol. 2007;81: 2485–2496. doi: 10.1128/JVI.01594-0617151104
16. Sampah MES, Shen L, Jilek BL, Siliciano RF, Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance. Proc Natl Acad Sci U S A. 2011;108: 7613–7618. doi: 10.1073/pnas.101836010821502494
17. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy. Science. 1997;278: 1295–1300. doi: 10.1126/science.278.5341.12959360927
18. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. 2003;9: 727–728. doi: 10.1038/nm88012754504
19. Archin NM, Vaidya NK, Kuruc JD, Liberty AL, Wiegand A, Kearney MF, et al. Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci U S A. 2012;109: 9523–9528. doi: 10.1073/pnas.112024810922645358
20. Kiselinova M, Geretti AM, Malatinkova E, Vervisch K, Beloukas A, Messiaen P, et al. HIV-1 RNA and HIV-1 DNA persistence during suppressive ART with PI-based or nevirapine-based regimens. J Antimicrob Chemother. 2015;70(12):3311–6. doi: 10.1093/jac/dkv25026324076
21. Crooks AM, Bateson R, Cope AB, Dahl NP, Griggs MK, Kuruc JD, et al. Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies. J Infect Dis. 2015;212(9):1361–5. doi: 10.1093/infdis/jiv21825877550